Under the terms of the agreement, Alchemab will be taking the programme through early Phase 1 clinical trials after which Lilly will lead all further development and commercialisation. Alchemab's ...

SEED Therapeutics Inc. ("SEED"), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery ...

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...